London, May 25, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Biologics Fill / Finish Services Market (2nd Edition) 2021 – 2030” report to its list of offerings. In pursuit of ...

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service ...

The fill-finish market—a traditionally stable one—is increasingly adopting new technologies. Research from our 12th Annual Report and Survey of Biopharmaceutical Manufacturing, and other studies ...

LONDON, July 18, 2019 /PRNewswire/ -- Roots Analysis has announced the addition of "Biologics Fill / Finish Services Market, 2019 - 2030" report to its list of offerings. Despite the fact that ...

Automation, single-use systems, smaller footprints, and new drug delivery devices define trends for fill/finish outsourcing. Fill/finish operations have traditionally been among the most commonly ...

As medicines shift from one-size-fits-all treatments to personalized and small-batch drugs for rare diseases, the fill/finish industry is modernizing to address changing manufacturing needs. Parallel ...

SPOKANE, Wash.--(BUSINESS WIRE)--Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological ...

DUBLIN--(BUSINESS WIRE)--The "Biologics Fill Finish Services Market Industry Trends and Global Forecasts to 2035, by Type of Primary Packaging Container, Type of Biologic Manufactured, Scale of ...

DUBLIN--(BUSINESS WIRE)--The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service Offered, Type of FDF, ...

The MarketWatch News Department was not involved in the creation of this content. DELRAY BEACH, Fla., Aug. 19, 2025 /PRNewswire/ -- The global Fill Finish Manufacturing Market, valued at US$16.85 ...

The development of genetically engineered drugs is a relatively new endeavor. Insulin, as Humulin® from Eli Lilly & Co. and approved in 1982, was the first genetically engineered biopharmaceutical.